Antiangiogenic Therapy in the Current Landscape of NSCLC

Antiangiogenic Therapy in the Current Landscape of NSCLC

Episodes

Specialty:

All

Year:

All

EP. 1: Rationale Behind Antiangiogenic Therapy in NSCLC

April 19th 2018

EP. 2: Patient Selection for Frontline Bevacizumab in NSCLC

April 19th 2018

EP. 3: Treating NSCLC With Ramucirumab: The REVEL Trial

April 19th 2018

EP. 4: NSCLC: Rapid Progression Data in the REVEL Trial

April 19th 2018

EP. 5: Clinical Implications of the REVEL Trial in NSCLC

April 19th 2018

EP. 6: NSCLC: Mechanisms of Resistance to Antiangiogenic Therapy

April 19th 2018

EP. 7: Combination Strategies With VEGF-Targeted Therapy in NSCLC

April 19th 2018

EP. 8: Future Treatment Strategies in Non-Small Cell Lung Cancer

April 19th 2018

Trending on OncLive

ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma

Dr Wainberg on INCB161734 Activity in Refractory Pancreatic Cancer

China’s NMPA Accepts NDA for Opamtistomig in Pretreated Advanced Extrapulmonary NEC

European Commission Approves Teclistamab Plus Daratumumab for R/R Myeloma

ASCO Guideline Update Broadens First-Line Treatment Options for HER2+ Gastroesophageal Cancer